Engineered for execution, at any scale.
ABOUT
Science is advancing at exponential speed. The manufacturing infrastructure required to deliver it is stuck in the past. Electron Bio was founded by operators to close that gap.
THE PROBLEM WE SOLVE
A therapy can be designed faster than ever. Making it is the bottleneck. The supply chain is fragmented, opaque, rigid, and capital-intensive, and a new facility takes years to build. Patients wait months for a manufacturing slot. That is not a science problem. It is a logistics and infrastructure failure, and it is the one we work on.
Medicine can be designed in weeks. It still takes years to make.
We are not a traditional consulting firm, not a cleanroom manufacturer, and not a software company, though we operate across all three. Elite CMC expertise moves a program from compound selection to first-in-human. FAST GMP re-engineers the physical plant as modular, reconfigurable pods. Cerebex OS is the digital layer that runs it. Manufacturing integration ties external capacity into one coordinated network. Each part makes the others better.
Expertise, hardware, and software, under one roof.
WHAT WE BUILT
Get medicines to patients.
WHY WE EXIST
Impact is measured in one thing: therapies that reach patients. Needles in arms, product on the shelf. That is the only scoreboard we keep.
We run a small senior core and bring in vetted specialists per program. That is deliberate. It means the person advising you is the person who has done the work, and it means we can move without the overhead that slows larger firms down. We are selective about the programs we take, because we cannot manage risk we cannot see.
HOW WE WORK
A lean team, by design.
We are direct
If a timeline is not achievable, we say so before the contract, not after.
We stay accountable
One team owns the outcome, including the partners we bring in.
Complex, personalized, and rare-disease programs where speed decides the outcome.
We focus on the hard problems
AFFILIATIONS
Where we participate.
Alliance for mRNA Medicines, Alliance for Regenerative Medicine, and other institutions. We take part in board-level task force work on individualized therapies and manufacturing policy.
Work with us.
Tell us about your program and where it is stuck.